Last reviewed · How we verify
salbutamol pressurized metered dose inhaler
Salbutamol is a beta-2 adrenergic agonist that binds to beta-2 receptors on airway smooth muscle, causing relaxation and bronchodilation.
Salbutamol is a beta-2 adrenergic agonist that binds to beta-2 receptors on airway smooth muscle, causing relaxation and bronchodilation. Used for Acute relief of bronchospasm in asthma, Acute relief of bronchospasm in chronic obstructive pulmonary disease (COPD), Prevention of exercise-induced bronchospasm.
At a glance
| Generic name | salbutamol pressurized metered dose inhaler |
|---|---|
| Sponsor | University of Saskatchewan |
| Drug class | Beta-2 adrenergic agonist (short-acting) |
| Target | Beta-2 adrenergic receptor |
| Modality | Small molecule |
| Therapeutic area | Respiratory |
| Phase | FDA-approved |
Mechanism of action
Salbutamol activates beta-2 adrenergic receptors on bronchial smooth muscle cells, triggering a cascade that increases intracellular cAMP levels. This leads to smooth muscle relaxation and rapid airway dilation, relieving bronchoconstriction. The pressurized metered dose inhaler (pMDI) formulation delivers the drug directly to the lungs for rapid local effect.
Approved indications
- Acute relief of bronchospasm in asthma
- Acute relief of bronchospasm in chronic obstructive pulmonary disease (COPD)
- Prevention of exercise-induced bronchospasm
Common side effects
- Tremor
- Headache
- Nervousness or anxiety
- Palpitations
- Muscle cramps
- Tachycardia
Key clinical trials
- Anti-Inflammatory Reliever South Africa (PHASE3)
- Combination Short-Acting BroNchodilator and Inhaled Corticosteroid Rescue Therapy on Health Outcomes in Routine Care (PHASE4)
- Reversibility of Methacholine Induced Bronchoconstriction (PHASE4)
- Study of Inhaled Glucocorticosteroids/Long-Acting Bronchodilator Drugs in Subjects With Asthma That Have Been Taking Inhaled Glucocorticosteroids (Study P04705AM1) (PHASE3)
- Two Inhalation Methods Using a Pressurized Metered Dose Inhaler With Valved Holding Chamber to Assess Improvement in Lung Function After SABA Administration in Bronchial Asthma (NA)
- A Study to Assess the Efficacy and Safety of Budesonide/Albuterol Metered Dose Inhaler (BDA MDI/PT027) Used 4 Times Daily in Adults and Children 4 Years of Age or Older With Asthma (PHASE3)
- Continuation of TRAVERSE- LTS12551 Evaluating Dupilumab Safety in Patients With Asthma (Long-Term Follow-Up) (PHASE3)
- Single Blind Cross-over Dose Response Study in Subjects of Two Inhalers of Salmeterol and Fluticasone Propionate (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: